Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis | Zendy

Dami A. Collier | Zendy; Collins Iwuji | Zendy; Anne Derache | Zendy; Túlio de Oliveira | Zendy; hlanhla Okesola | Zendy; Alexandra Calmy | Zendy; François Dabis | Zendy; Deenan Pillay | Zendy; Ravindra K. Gupta | Zendy

Open Access

Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis

Author(s) -

Dami A. Collier,

Collins Iwuji,

Anne Derache,

Túlio de Oliveira,

hlanhla Okesola,

Alexandra Calmy,

François Dabis,

Deenan Pillay,

Ravindra K. Gupta

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix015

Subject(s) - medicine , lopinavir , interquartile range , cumulative incidence , hazard ratio , viral load , ritonavir , cohort , emtricitabine , cohort study , pediatrics , immunology , confidence interval , human immunodeficiency virus (hiv) , antiretroviral therapy

Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. Maximizing their effectiveness is imperative.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research